IMF Videos Search Content For Healthcare Professional (166) Healthcare Provider (165) Care Partner (128) Patient (128) Series - Any - About the IMF (2) ASCO/EHA (163) ASH (230) Ask Dr. Durie (259) Black Swan Research Initiative (7) Community Workshops (33) Emerging Therapies (20) Facebook Live (21) Health Equity (16) IMF History (4) IMWG (13) Inspirational (16) Living Well with Myeloma (34) Myeloma in a Minute (19) Myeloma Made Simple (15) Myeloma University (12) NLB Webcasts (1) Patient & Family Webinar (27) Q&A (19) Recent News and Developments (4) Treatments (4) Trending Searches in Myeloma (1) Topics Clinical Trials (136) Financial Considerations (1) Frontline Therapy (34) Health Equity (10) Inspirational Stories (1) Lab & Imaging Tests (26) Lifestyle (4) Mental & Emotional Health (1) Public Policy & Advocacy (1) Recorded Webinars (2) Relapse/Refractory Myeloma (80) Research Updates (151) Symptom Management (8) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (31) High-Risk Myeloma (29) High-risk Smoldering Myeloma (13) Late Relapse (4–6 Lines of Therapy) (63) MGUS (18) Newly Diagnosed (Pre-Treatment or First Treatment) (52) Smoldering Myeloma (22) Types of Therapy Immunomodulatory drugs (IMiDs) (57) Immunotherapies (CAR T; BiTE, etc.) (60) Monoclonal antibodies (49) Proteasome inhibitors (50) Stem cell transplant (38) Steroids (21) Supportive Care (17) Year Published 2026 (7) 2025 (24) 2024 (23) 2023 (21) 2022 (34) 2021 (27) 2020 (18) 2019 (32) 2018 (30) 2017 (5) 2016 (3) 2015 (6) Trusted Voices Dr. María-Victoria Mateos (8) Dr. Saad Usmani (4) Dr. Shaji Kumar (4) Dr. Brian GM Durie (3) Dr. Joseph Mikhael (3) Dr. Sagar Lonial (1) Dr. Sigurður Kristinsson (1) Dr. Tom Martin (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Safety and Efficacy of Fully Human BCMA CAR T Cells in Combination with a Gamma Secretase Inhibitor January 6, 2022 ASH Daratumumab Plus RVd in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma: Updated Analysis of Griffin after 24 Months of Maintenance December 23, 2021 ASH Rationale for Selinexor Treatment in Daratumumab-Refractory MM Patients Identified By Paired Ex Vivo Drug Sensitivity and RNA-Seq December 23, 2021 ASH Monoclonal Gammopathy of Undetermined Significance and COVID-19: Results from iStopMM December 22, 2021 ASH IRd Vs Rd Maintenance after Autologous Stem Cell Transplant in Newly Diagnosed Multiple Myeloma Pts: Results of the Spanish GEM2014MAIN Trial December 22, 2021 ASH Suboptimal Humoral and Cellular Immune Response to SARS-CoV-2 RNA Vaccination in Myeloma Patients Is Associated with Anti-CD38 and BCMA-Targeted Treatment December 22, 2021 ASH Estimating Selection Bias in Previous MGUS Research – the Importance of Screening: Results from the Population-Based Screening Study iStopMM December 20, 2021 ASH Synergetic Effects of Belantamab Mafodotin Plus Inducible T-Cell Co-Stimulator Agonist (aICOS) Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma December 17, 2021 ASH Dara+IRD As Extended Induction and Consolidation Followed By Lenalidomide Maintenance December 17, 2021 ASH Updated Clinical and Correlative Results from the Phase I CRB-402 Study of the BCMA-Targeted CAR T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma December 17, 2021 ASH Dara-KRd, Autologous Transplantation and MRD Response-Adapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the MASTER Trial December 16, 2021 ASH Global Treatment Patterns and Outcomes Among Patients with Chromosome Translocation (11;14)-Positive Multiple Myeloma December 15, 2021 ASH Load More
